Exploration of Targeted Anti-tumor Therapy

Table 4.

Ongoing studies

Trial	Phase	Setting	Stage	Patients	Treatment	Primary end points
Beverly trial NCT02633189	III	Metastatic, first line	IV stage	200	Erlotinib + Bevacizumab vs. Erlotinib	PFS
Brilliant trial NCT02655536	II	Metastatic, first line	IV stage, brain metastases	109	Erlotinib + Bevacizumab vs. Erlotinib	PFS
Ava-Ta trial NCT03126799	II	Metastatic, first line	IV stage	128	Erlotinib + Bevacizumab vs. Bevacizumab	PFS
NCT02803203	I/II	Metastatic, first line	IV stage	50	Osimertinib + Bevacizumab	PFS
BOOSTER NCT03133546	II	Metastatic, second line	IV stage, T790M mutated	155	Osimertinib + Bevacizumab vs. Osimertinib	PFS
ACCRU NCT02971501	II	Metastatic, first line	IV stage, brain metastases	112	Osimertinib + Bevacizumab vs. Osimertinib	PFS
OWONBNSCLCLM NCT04148898	II	Metastatic, first line	IV stage, leptomeningeal metastases	80	Osimertinib + Bevacizumab vs. Osimertinib	ORR and iPFS
NCT04181060	III	Metastatic, first line	IV stage	300	Osimertinib + Bevacizumab vs. Osimertininib	PFS
NCT03909334	II	Metastatic, first line	IV stage, also in patients with brain metastases	150	Osimertinib + Ramucirumab vs. Osimertinib	PFS
NCT02789345	I	Metastatic, first line	IV stage, T790M mutated	74	Osimertinib + Ramucirumab + Necitumumab	DLTs

iPFS: intracranial progression-free survival